BIONYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO.B

BIO-RAD LABORATORIES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$352.82−0.88 (-0.25%)

Close on Oct 19, 2026

Market cap: $9.46B
P/E (TTM): 42.8
Dividend yield: –

BIO-RAD LABORATORIES, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	2,583	2,567	2,671	2,802	2,923	2,546	2,312	2,289	2,160	2,068	2,019	2,175	2,133	2,069	2,074	1,927	1,784	1,764
Cost of Revenue	1,243	1,188	1,244	1,235	1,284	1,108	1,055	1,066	972	930	898	997	954	914	895	836	784	802
Gross Profit	1,340	1,379	1,427	1,567	1,638	1,438	1,257	1,223	1,188	1,138	1,122	1,179	1,178	1,155	1,179	1,091	1,000	963
Research & Development	276	296	247	257	261	218	203	199	250	206	193	220	211	209	178	172	164	160
Selling, General & Admin	844	814	842	828	877	799	825	835	807	815	762	808	798	682	696	635	601	591
Operating Income	47	269	338	483	500	421	230	-103	119	56	167	150	169	264	305	284	231	183
Interest Expense	49	49	49	38	1.55	22	23	24	23	23	22	22	61	51	53	64	47	32
Interest & Investment Income	96	82	101	58	19	18	31	27	19	15	10	14	13	11	8.20	5.20	5.70	–
Other Non-Operating Income	90	90	107	45	27	24	26	37	11	14	11	-0.10	13	22	7.58	3.88	6.87	0.35
Merger & Restructuring Charges	–	–	–	0	76	–	–	–	–	13	–	–	–	–	–	–	–	–
Asset Impairment Charges	173	0	0	0	0	0	0	293	12	62	0	0	–	–	0	0	3.80	29
Gain (Loss) on Sale of Assets	0	0	-2.50	-1.40	0	-12	0	4.10	0	0	-0.30	-0.40	-0.50	3.80	-0.20	-0.50	–	–
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	-20	–	–	–	–	–	–
Pretax Income	996	-2,343	-850	-4,704	5,449	4,918	2,261	513	98	42	146	132	112	230	246	220	186	143
Income Tax Expense	236	-498	-213	-1,077	1,195	1,104	502	147	-24	16	37	43	35	64	67	33	37	45
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	–	113	89	78	166	179	187	149	98
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	0	0	0.02	0.07	-0.20	1.45	4.55	8.75
Net Income	760	-1,844	-637	-3,628	4,254	3,814	1,759	366	122	26	109	89	78	165	179	185	145	90
EPS (Basic)(per share)	27.87	-65.36	-21.82	-121.79	142.61	128.13	58.93	12.25	4.12	0.88	3.74	3.08	2.72	5.85	6.39	6.70	5.28	3.30
EPS (Diluted)(per share)	27.85	-65.36	-21.82	-121.79	140.83	126.47	58.27	12.10	4.07	0.88	3.71	3.05	2.69	5.78	6.29	6.59	5.20	3.24
Shares Outstanding (Basic, Weighted)(shares)	27	28	29	30	30	30	30	30	30	29	29	29	29	28	28	28	27	27
Shares Outstanding (Diluted, Weighted)(shares)	27	28	29	30	30	30	30	30	30	30	29	29	29	29	28	28	28	28
EBITDA	213	421	484	620	638	560	364	35	268	199	299	300	317	395	426	393	333	–
Provision for Credit Losses	1.40	0	0	7.50	0	0	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 51.9%
Operating margin: 2.1%
Net margin: 8.6%
Return on equity, FY2025: 10.8%

Financial strength

Current ratio: 3.14
Debt to equity: 0.11
Debt to assets: 7.8%
Cash to current liabilities: 53.8%

Valuation

P/E ratio: 42.8
Price to sales: 3.65
Price to book: 1.32
Dividend yield: –